Skip to main content
. 2022 Sep 15;13:970588. doi: 10.3389/fimmu.2022.970588

Figure 2.

Figure 2

Outcome prediction of constructed GILncSig and verification as a valid prognostic factor independent of key clinical features. (A), (C), (E) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in the training set, testing set and the combined TCGA cohort, respectively. Statistical analysis was performed using the log-rank test. (B), (D), (F) Time-dependent ROC curve analysis of GILncSig at 3 years in the training set, testing set and the combined TCGA cohort. (G) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in young-patient group (age ≤ 65). (H) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in old-patient group.